Last edition
News about
Apriori Bio, A*STAR IDL Partner to Develop Next-Gen AI-Designed saRNA Flu Vaccines
Apriori Bio, a Flagship Pioneering company focused on creating variant-resilient vaccines, has announced a strategic research partnership with the ASTAR Infectious Diseases Labs (ASTAR IDL) to co-develop next-generation self-amplifying RNA (saRNA) vaccines for seasonal and pandemic influenza.
Thermo Fisher Opens East Coast Collaboration Center for Advanced Therapeutics
Thermo Fisher Scientific has opened a new East Coast Collaboration Center at BioLabs in Philadelphia, offering advanced lab space and expert support to help researchers accelerate the development of cell and gene therapies from early-stage discovery to clinical readiness.
HRV Pharma, MetroChem Form Multi-Year CDMO Alliance for High-Value API Development
HRV Global Life Sciences (HRV Pharma), India’s first integrated virtual API and pharmtech company, has entered into a multi-year CDMO partnership with MetroChem API, a leading player in API development and manufacturing.
Piramal Pharma Solutions' Grangemouth Facility Receives Updated MHRA GMP Certificates
Piramal Pharma Solutions's Grangemouth facility in the UK has received updated MHRA GMP certificates following a successful compliance report and desktop inspection.
EU Approves Insmed's BRINSUPRI, the First Treatment for Non-CF Bronchiectasis
The European Commission has approved BRINSUPRI as the first treatment for Non-Cystic Fibrosis Bronchiectasis, offering a new option for patients with this serious, progressive lung disease. The first-in-class DPP1 inhibitor was granted accelerated assessment by the EMA, reflecting its significant public health importance.
Marksans Pharma Subsidiary Secures USFDA Approval for Loperamide Hydrochloride Tablets USP, 2 mg
Marksans Pharma's wholly owned subsidiary, Marksans Pharma Inc., has received final approval from the US Food and Drug Administration (USFDA) for its Abbreviated New Drug Application (ANDA) for Loperamide Hydrochloride Tablets USP, 2 mg (OTC).
AbbVie Receives FDA Approval for EPKINLY Combo in Relapsed/Refractory Follicular Lymphoma
AbbVie has secured FDA approval for EPKINLY in combination with rituximab and lenalidomide (EPKINLY + R2), marking the first bispecific antibody combo therapy available for patients with relapsed or refractory follicular lymphoma after at least one prior systemic treatment.
Rockwell Automation Expanding US Footprint with New Greenfield Manufacturing Site
Rockwell Automation to build new greenfield manufacturing site in Southeastern Wisconsin as part of its USD 2 billion investment plan to strengthen US manufacturing and digital capability.
GSK, Fleming Initiative Launch AI-Driven Grand Challenges to Target AMR
These initiatives bring together leading scientific expertise and advanced technologies—including AI—to tackle urgent gaps in antibiotic discovery, fungal infection treatment, immune response understanding, disease prediction, clinical prescribing, and global policy engagement.
Union Health Minister Launches National Action Plan on Antimicrobial Resistance 2.0
Union Minister of Health and Family Welfare Jagat Prakash Nadda on Tuesday (18 November) launched the second version of the National Action Plan on Antimicrobial Resistance (NAP-AMR 2025–29), reinforcing India’s commitment to combating the growing threat of AMR.
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy